Does zinc carnosine heal leaky gut and protect the stomach lining?

When zinc and carnosine are bound together as a chelate, they form a stable complex that resists breakdown in stomach acid. This allows the compound to adhere to the gastric and intestinal mucosa rather than being absorbed quickly into the bloodstream¹. Once adhered, it delivers both zinc and carnosine's benefits directly at the tissue level.

Tight junction support. The gut lining is held together by proteins called tight junctions — occludin, claudin, and others. Zinc carnosine increases the expression and stability of these proteins. Research shows it reduces the phosphorylation (and thus destabilization) of occludin and claudin, which keeps the junctions intact and limits the passage of endotoxins and undigested proteins into the bloodstream¹.

Stimulating repair. The compound promotes the migration and proliferation of gut epithelial cells, effectively accelerating the natural process by which the gut lining replaces damaged cells. It also stimulates the production of mucus and growth factors involved in mucosal healing⁴.

Anti-inflammatory and antioxidant action. Both zinc and carnosine independently suppress inflammatory cytokines like TNF-alpha and IL-8 in gut tissue, and the complex does this more powerfully than either alone. This makes it relevant not just for structural repair but for calming underlying inflammation that drives gastritis and colitis⁵.

Practical Uses

Leaky gut and NSAID-induced intestinal damage. NSAIDs like ibuprofen and aspirin are well-known for damaging the gut lining. A controlled study found that zinc carnosine significantly protected against NSAID-induced small intestinal permeability, reducing injury markers in human volunteers¹.

Exercise-induced gut permeability. Intense exercise temporarily increases gut permeability as blood is diverted away from the intestines. A double-blind crossover study in healthy volunteers found that 14 days of zinc carnosine supplementation truncated exercise-induced gut permeability increases by approximately 70%, comparable to bovine colostrum².

H. pylori support. Several clinical trials have examined zinc carnosine (polaprezinc) as an add-on to standard H. pylori eradication protocols. Meta-analyses report improved eradication rates and better tolerability when combined with conventional triple therapy. The compound appears to reinforce mucosal defenses and reduce the inflammation that makes H. pylori infections more damaging⁵.

Typical dosage. Most clinical studies use 75 mg of zinc carnosine twice daily (150 mg/day total). This delivers approximately 16 mg of elemental zinc — within safe daily ranges. Longer-term use beyond 3 months should be balanced with adequate copper intake, as high zinc can deplete copper.

See our zinc page for more on zinc's broader roles, and our leaky gut page for the full picture on intestinal permeability.

Key structural study (Mahmood et al., 2007). Published in Gut, this foundational study examined zinc carnosine's mechanisms in rat models and human gut cell lines. The compound stabilized tight junction proteins (occludin, claudin) at concentrations achievable in the gut lumen following oral dosing. It also demonstrated dose-dependent protection against gastric mucosal injury — a 38% reduction at 1 mg/ml and 75% reduction at 5 mg/ml. Separately, it promoted epithelial cell migration in wound-healing assays, suggesting active repair rather than passive protection¹.

Exercise gut permeability RCT (Davison et al., 2016). This four-arm, double-blind, placebo-controlled crossover trial enrolled 8 healthy volunteers who completed standardized exercise protocols at 2 and 14 days after beginning treatment. At baseline, the lactulose:rhamnose (L:R) ratio — a validated marker of gut permeability — was 0.32. After exercise, it rose 3-fold to 1.0 in the placebo arm. Fourteen days of zinc carnosine supplementation truncated this rise by approximately 70%, a finding that reached statistical significance. The combined zinc carnosine plus bovine colostrum arm showed no additional benefit over either alone².

Hewlings and Kalman review (2020). This narrative review in Nutrients compiled evidence across GI indications, including gastric ulcers (Japan approval), H. pylori eradication, NSAID-induced injury, oral mucositis, and radiation esophagitis. The authors concluded that the safety profile is well-established — no serious adverse events have been reported in clinical use spanning over two decades — and that the compound's localized mucosal adherence is the key mechanistic advantage over elemental zinc supplementation³.

Efthymakis and Neri systematic review (2022). This more recent review examined human clinical data specifically, concluding that zinc carnosine has meaningful evidence for gastric ulcers, functional dyspepsia, and intestinal permeability conditions. The authors noted that while sample sizes in existing trials tend to be small, the consistency of findings across different GI pathologies is notable. They identified H. pylori eradication support and leaky gut as the most clinically relevant current applications and called for larger RCTs⁴.

Li et al. on polaprezinc (2021). This review in Experimental and Therapeutic Medicine covered broader applications including radiation-induced mucositis, taste disorders in chemotherapy patients, and experimental models of sepsis and colitis. Mechanistically, the authors highlighted zinc carnosine's ability to scavenge reactive oxygen species, suppress NF-κB activation, and maintain mucosal prostaglandin levels — all contributing to its gastroprotective and anti-inflammatory profile⁵.

Strength of evidence. The evidence base is moderate. Zinc carnosine has robust mechanistic data and a long clinical track record in Japan, where it has been used as a prescription drug for 30+ years. Human RCT data remains limited in scale — most trials have 10–50 participants — but the consistency of positive findings across leaky gut, H. pylori, NSAID injury, and inflammatory conditions is encouraging. This is not a compound where evidence is speculative; the mechanism is understood and the outcomes replicate across study types. The main open question is whether benefits persist long-term and whether the supplement form matches the pharmaceutical-grade compound used in Japanese trials.